← Back to Clinical Trials
Recruiting NCT06435611

Adiposity, Cardiometabolic and Neurocognitive Health Among Ethnic Groups: a Feasibility and Pilot Study

Trial Parameters

Condition Metabolic Disease
Sponsor King's College Hospital NHS Trust
Study Type OBSERVATIONAL
Phase N/A
Enrollment 10
Sex ALL
Min Age 18 Years
Max Age 55 Years
Start Date 2023-11-15
Completion 2023-12-30

Brief Summary

The goal of this pilot and feasibility study is to is to test the feasibility of conducting a cross-sectional study on adiposity and cardiometabolic and neurocognitive risk factors at Kings College Hospital NHS Foundation Trust (KCH). The main aim is to assess and compare anthropometric measurements of adiposity (weight, Body Mass Index (BMI), Waist Circumference (WC), Waist-to-Hip ratio (WHR), Neck circumference (NC)), liver fat (hepatic steatosis and fibrosis), cardiometabolic risk factors (dyslipidemia, insulin resistance, hypertension) and neurocognitive risk factors among participants, according to their ethnic background. Participants will come at KCH for one visit and will have their anthropometric measurements and cardio-metabolic profile assessed. They will also perform questionnaires on lifestyle, socio-economic status and neuro-cognitive health during their visit.

Eligibility Criteria

Inclusion Criteria: * Men and women aged ≥18 years old * Body mass index (BMI) ≥ 30 kg/m2 Exclusion Criteria: * Severe obesity (BMI \> 50 kg/m2) * Pregnancy (positive urine hCG) or a recent pregnancy (in the past 6 months) * Known active chronic hepatic diseases * Known diagnosis of human immunodeficiency virus * Pre-established diagnosis of advanced renal failure (estimated Glomerular Filtration Rate (eGFR) \<30 ml/min) * Diagnosis of decompensated heart failure * History of bariatric surgery * Uncontrolled thyroid disease * Current use of the following medication: steroids (oral or injections only), weight-loss medication including over-the-counter products, glucagon-like peptide 1 (GLP-1) agonists , Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors

Related Trials